Combined tetrahydrocannabinol and cannabidiol to treat pain in epidermolysis bullosa: a report of three cases
N H B Schräder, J C Duipmans, B Molenbuur, A P Wolff, M F Jonkman, N H B Schräder, J C Duipmans, B Molenbuur, A P Wolff, M F Jonkman
Abstract
Epidermolysis bullosa (EB) is a genetic blistering disorder characterized by intense pain related to disease pathology and care-based interventions. Opioid-based therapies underpin pain care in EB; however, they are unable to provide adequate analgesia in a significant proportion of patients. Cannabinoid-based medicines (CBMs) have been studied increasingly for pain conditions of various aetiologies and pose as a novel dimension for pain care in EB. We present three patients with EB who were prescribed pharmaceutical-grade sublingually administered CBMs comprising tetrahydrocannabinol and cannabidiol. All three patients reported improved pain scores, reduced pruritus and reduction in overall analgesic drug intake.
© 2018 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
References
- Fine JD, Johnson LB, Weiner M, Suchindran C. Assessment of mobility, activities and pain in different subtypes of epidermolysis bullosa. Clin Exp Dermatol 2004; 29:122–7.
- Goldschneider KR, Good J, Harrop E et al Pain care for patients with epidermolysis bullosa: best care practice guidelines. BMC Med 2014; 12:178.
- de Hoop B, Heerdink ER, Hazekamp A. Medicinal cannabis on prescription in the Netherlands: statistics for 2003–2016. Cannabis Cannabinoid Res 2018; 3:54–5.
- Chelliah MP, Zinn Z, Khuu P, Teng JMC. Self‐initiated use of topical cannabidiol oil for epidermolysis bullosa. Pediatr Dermatol 2018; 35:e224–7.
- Yuen WY, Frew JW, Veerman K et al Health‐related quality of life in epidermolysis bullosa: validation of the Dutch QOLEB questionnaire and assessment in the Dutch population. Acta Derm Venereol 2014; 94:442–7.
- Von Bischhoffshausen S, Ivulic D, Alvarez P et al Recessive dystrophic epidermolysis bullosa results in painful small fibre neuropathy. Brain 2017; 140:1238–51.
- Schräder N, Yuen W, Jonkman M. Pain quality assessment scale for epidermolysis bullosa. Acta Derm Venereol 2017; 98:346–9.
- Finnerup NB, Attal N, Haroutounian S et al Pharmacotherapy for neuropathic pain in adults: a systematic review and meta‐analysis. Lancet Neurol 2015; 14:162–73.
- Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. Pain 2011; 152 (Suppl. 3):S2–15.
- Whiting PF, Wolff RF, Deshpande S et al Cannabinoids for medical use a systematic review and meta‐analysis. JAMA 2015; 313:2456–73.
- Thomas BF, Pollard GT. Preparation and distribution of cannabis and cannabis‐derived dosage formulations for investigational and therapeutic use in the United States. Front Pharmacol 2016; 7:285.
- Castillo PE, Younts TJ, Chávez AE et al Endocannabinoid signaling and synaptic function. Neuron 2012; 76:70–81.
- Russo EB. Cannabinoids in the management of difficult to treat pain. Ther Clin Risk Manag 2008; 4:245–59.
- Mounessa JS, Siegel JA, Dunnick CA, Dellavalle RP. The role of cannabinoids in dermatology. J Am Acad Dermatology 2017; 77:188–90.
- Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9‐tetrahydrocannabinol, cannabidiol and delta9‐tetrahydrocannabivarin. Br J Pharmacol 2008; 153:199–215.
Source: PubMed